SPH
SPH
A national pharmaceutical industry group headquartered in Shanghai
Shanghai Pharmaceutical Group Corporation Limited (the Company) (HKSE stock code: 02607; SSE stock code: 601607) is a national pharmaceutical industry group headquartered in Shanghai. The Company's main business covers pharmaceutical research and development and manufacturing, distribution and retailing, with an operating income of 105.5 billion yuan in 2015, the Company's overall ranking is among the best in China, and it is one of the few listed pharmaceutical companies in China with a leading position in both the pharmaceutical products and distribution markets, selected as a sample stock of the SSE 180 Index and the CSI 300 Index, and its H shares are selected as a constituent stock of the Hang Seng Index, a constituent stock of the Morgan Stanley China Index ( (MSCI).
- All
- News
- Analysis
- Research
In depth
Briefing Jan 13, 2022 10:05 AM
· Healthcare
West Lake Omei won hundreds of millions of yuan of pre-A round of financing to help clinical diagnosis and AI new drug research and development based on proteome big data
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Jan 12, 2022 09:28 AM
· Healthcare
Zhenge biology obtained US $100 million in round C financing, led by Goldman Sachs and Sofina
Briefing Jan 10, 2022 09:00 PM
· Healthcare
Bristol Myers Squibb entered the development of IPSC derived allogeneic cell therapy with more than US $3 billion
Briefing Jan 10, 2022 11:16 AM
· Healthcare
Lanjing microorganism completed a total of RMB 1.5 billion of Series B financing and accelerated the implementation of the "T-type" development strategy
Briefing Jan 10, 2022 09:37 AM
· Healthcare
Synthetic biology enterprise Lanjing microorganism completed a total of 1.5 billion yuan of Series B financing
In depth
Healthcare
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM
Briefing Jul 19, 2021 04:38 PM
Fitch confirmed that Wanzhou International, the parent company of Shuanghui, is rated as' BBB + 'with a stable outlook.
See more
Related Companies
EqualOcean Analysis
- Wuxi Apptec Embraces a More Health-Conscious China
- Four Growing Stocks to Watch in the Dynamic Chinese Market
- Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.